WAS and Bruton-type agammaglobulinemia: Each patient in the blinded study was deficient in the signature peptide specific for their respective disease [i.e., XLA patient lacking Bruton's Tyrosine Kinase (BTK) and WAS patient missing WAS protein (WASP), etc.].